Ligand Pharmaceuticals Inc. | Mid-cap | Healthcare
$177.73
-2.52%
| Ligand Stock Comparison:
Ligand vs VertexLigand vs AlnylamLigand vs MadrigalLigand vs Bio-TechneLigand vs Corcept TherapeuticsLigand vs S&P 500 | Market
TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Mar 2025

Income Metrics

Revenue 45.3M
Gross Profit 40.5M 89.30%
Operating Income -36.7M -80.87%
Net Income -42.5M -93.64%
EPS (Diluted) $-2.21

Balance Sheet Metrics

Total Assets 905.4M
Total Liabilities 109.9M
Shareholders Equity 795.5M
Debt to Equity 0.14

Cash Flow Metrics

Operating Cash Flow -35.0M
Free Cash Flow -27.5M

Revenue & Profitability Trend

Ligand Income Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Revenue i 167.1M 131.3M 196.2M 241.5M 163.6M
Cost of Goods Sold i 11.1M 10.5M 52.8M 62.2M 30.4M
Gross Profit i 156.1M 120.8M 143.4M 179.4M 133.1M
Gross Margin % i 93.4% 92.0% 73.1% 74.3% 81.4%
Operating Expenses
Research & Development i 21.4M 24.5M 36.1M 32.1M 40.5M
Selling, General & Administrative i 78.7M 52.8M 70.1M 46.8M 60.0M
Other Operating Expenses i - - - -37.6M 600.0K
Total Operating Expenses i 100.1M 77.3M 106.1M 41.3M 101.1M
Operating Income i 23.0M 9.8M 3.0M 103.9M 20.4M
Operating Margin % i 13.8% 7.5% 1.5% 43.0% 12.5%
Non-Operating Items
Interest Income i 8.1M 7.7M 2.0M 886.0K 8.1M
Interest Expense i 3.0M 656.0K 1.8M 19.6M 27.4M
Other Non-Operating Income -25.5M 46.8M 32.7M -12.9M 243.0K
Pre-tax Income i 2.5M 63.7M 36.0M 72.2M 1.3M
Income Tax i 6.6M 9.8M 41.2M -4.1M -5.3M
Effective Tax Rate % i 260.1% 15.5% 114.5% -5.7% -410.7%
Net Income i -4.0M 52.2M -33.4M 57.1M -3.0M
Net Margin % i -2.4% 39.7% -17.0% 23.7% -1.8%
Key Metrics
EBITDA i 11.4M 51.2M 60.6M 148.0M 56.5M
EPS (Basic) i $-0.22 $3.02 $-1.98 $3.46 $-0.18
EPS (Diluted) i $-0.22 $2.94 $-1.98 $3.34 $-0.18
Basic Shares Outstanding i 18290000 17298000 16868000 16630000 16185000
Diluted Shares Outstanding i 18290000 17298000 16868000 16630000 16185000

Income Statement Trend

Ligand Balance Sheet From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Assets
Current Assets
Cash & Equivalents i 72.3M 23.0M 45.0M 19.5M 47.6M
Short-term Investments i 183.9M 147.4M 166.9M 321.6M 363.6M
Accounts Receivable i 38.4M 32.9M 30.4M 85.5M 56.8M
Inventory i 14.1M 24.0M 13.3M 27.3M 26.5M
Other Current Assets 16.9M 2.7M 2.3M 3.6M 3.8M
Total Current Assets i 331.6M 237.4M 263.6M 464.8M 500.6M
Non-Current Assets
Property, Plant & Equipment i 9.7M 9.5M 15.0M 19.4M 22.7M
Goodwill i 477.1M 573.6M 564.0M 598.1M 985.6M
Intangible Assets i 266.6M 366.9M 352.6M 386.8M 606.3M
Long-term Investments 10.6M - - - -
Other Non-Current Assets 7.0M 6.1M 10.3M 324.0M 44.4M
Total Non-Current Assets i 610.2M 549.8M 499.1M 832.8M 861.7M
Total Assets i 941.8M 787.2M 762.7M 1.3B 1.4B
Liabilities
Current Liabilities
Accounts Payable i 5.2M 2.4M 5.3M 8.4M 3.8M
Short-term Debt i 1.3M 410.0K 77.4M 1.4M 8.5M
Current Portion of Long-term Debt - - - - -
Other Current Liabilities 206.0K 256.0K 57.0K 13.6M 39.9M
Total Current Liabilities i 37.1M 16.8M 98.8M 41.7M 100.1M
Non-Current Liabilities
Long-term Debt i 5.8M 5.8M 10.3M 323.0M 447.9M
Deferred Tax Liabilities i 32.5M 31.6M 30.6M 30.9M 64.6M
Other Non-Current Liabilities 17.7M 3.0M 4.0M 25.4M 40.1M
Total Non-Current Liabilities i 74.2M 69.5M 66.4M 434.8M 552.6M
Total Liabilities i 111.3M 86.3M 165.2M 476.4M 652.8M
Equity
Common Stock i 20.0K 18.0K 17.0K 17.0K 16.0K
Retained Earnings i 499.0M 503.0M 450.9M 449.1M 392.0M
Treasury Stock i - - - - -
Other Equity - - - - -
Total Shareholders Equity i 830.4M 700.9M 597.5M 821.2M 709.5M
Key Metrics
Total Debt i 7.1M 6.2M 87.7M 324.4M 456.4M
Working Capital i 294.4M 220.6M 164.8M 423.1M 400.4M

Balance Sheet Composition

Ligand Cash Flow Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Operating Activities
Net Income i -4.0M 52.2M -33.4M 57.1M -3.0M
Depreciation & Amortization i 35.2M 35.6M 51.4M 50.9M 28.0M
Stock-Based Compensation i 41.1M 25.7M 60.3M 38.8M 30.7M
Working Capital Changes i 5.5M -34.4M 65.7M -57.0M -11.7M
Operating Cash Flow i 68.7M 93.3M 170.6M 67.4M 50.8M
Investing Activities
Capital Expenditures i -1.8M -3.5M -17.9M -8.8M -4.5M
Acquisitions i -172.2M -25.7M -750.0K 0 -383.3M
Investment Purchases i -226.4M -126.8M -51.2M -181.3M -422.5M
Investment Sales i 269.6M 194.2M 234.4M 221.3M 1.0B
Investing Cash Flow i -133.3M 38.2M 163.5M 30.0M 230.3M
Financing Activities
Share Repurchases i - - 0 0 -78.0M
Dividends Paid i - - - - -
Debt Issuance i - - - - 0
Debt Repayment i -25.0K -76.9M -261.0M -164.9M -231.8M
Financing Cash Flow i 31.6M -82.4M -279.2M -171.5M -313.6M
Free Cash Flow i 77.4M -4.3M 119.9M 70.0M 50.1M
Net Change in Cash i -33.1M 49.1M 54.9M -74.1M -32.4M

Cash Flow Trend

Ligand Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 46.27
Forward P/E 30.63
Price to Book 4.29
Price to Sales 19.03
PEG Ratio -0.43

Profitability Ratios

Profit Margin -40.44%
Operating Margin 20.41%
Return on Equity -9.46%
Return on Assets -0.99%

Financial Health

Current Ratio 5.45
Debt to Equity 0.69
Beta 0.83

Per Share Data

EPS (TTM) $-4.05
Book Value per Share $42.68
Revenue per Share $9.88

Peer Financial Comparison

Company Market Cap P/E Ratio P/B Ratio ROE Profit Margin Debt/Equity
lgnd 3.6B 46.27 4.29 -9.46% -40.44% 0.69
Vertex 108.0B 29.16 6.12 22.77% 31.86% 8.89
Alnylam 60.2B -209.88 240.24 -257.83% -12.96% 1,093.31
Madrigal 9.9B -19.95 13.93 -36.30% -54.68% 17.81
Bio-Techne 9.8B 136.85 5.08 3.68% 6.02% 23.14
Corcept Therapeutics 9.5B 80.64 14.96 21.70% 18.67% 1.04

Financial data is updated regularly. All figures are in the company's reporting currency.